| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | -0.24 | 0.2 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.2 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.2 |